Literature DB >> 16598554

[Postoperative antithrombotic treatment in diabetic patients].

M Klutmann1, C Tillmanns, D C Gulba.   

Abstract

Diabetes mellitus patients after aorto-coronary bypass operation constitute a patient cohort at largely increased risk for secondary coronary events. Antiplatelet agents and antithrombotic agents are applied for secondary prevention. Up to now, secondary prevention has not been addressed specifically in the cohort of diabetic patients after bypass operation. Hence therapeutic recommendations are derived from the global cohort of CAD patients and based on risk assessment rather than on specific data. Since diabetic patients after myocardial infarction are at particularly high risk, combined therapy with clopidogrel and ASS may be considered even with restricted resources in the health system. Oral anticoagulation with coumadin constitutes an effective alternative to dual anti-platelet therapy. Under specific conditions (ventricular aneurysms, EF < 30%, or certain conditions in coronary anatomy) oral anticoagulants should be considered more liberally than currently.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598554     DOI: 10.1007/s00392-006-1124-x

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  8 in total

1.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Authors:  S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

2.  Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.

Authors:  M Pyörälä; H Miettinen; P Halonen; M Laakso; K Pyörälä
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-02       Impact factor: 8.311

3.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

4.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

5.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

6.  Warfarin, aspirin, or both after myocardial infarction.

Authors:  Mette Hurlen; Michael Abdelnoor; Pål Smith; Jan Erikssen; Harald Arnesen
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

7.  Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys.

Authors:  K Pyörälä; S Lehto; D De Bacquer; J De Sutter; S Sans; U Keil; D Wood; G De Backer
Journal:  Diabetologia       Date:  2004-07-02       Impact factor: 10.122

8.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

  8 in total
  2 in total

Review 1.  Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature.

Authors:  J Carlsson; B von Wagenheim; R Linder; T M Anwari; J Qvist; I Petersson; T Magounakis; B Lagerqvist
Journal:  Clin Res Cardiol       Date:  2006-12-22       Impact factor: 5.460

Review 2.  [Peri-operative adjustment and treatment of diabetes mellitus].

Authors:  J F Zander; A Risse
Journal:  Orthopade       Date:  2009-09-06       Impact factor: 1.087

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.